Berthelsen Program for Restoration of Intestinal Microbiota (B-PRIM)

B-PRIM

We live in spectacular times. Because of advances in microbial detection over the past 8 years the second body genome has been identified through the NIH sponsored human microbiome initiative. The 100 trillion intestinal bacteria that live in our GI tract, which possess more DNA and cells than seen in our body are a hidden factory producing chemicals that circulate in our blood effect the brain and body metabolism.   An unhealthy Western diet and high usage of unnecessary antibiotics has created a medical condition known as “dysbiosis”, or abnormal microbial patterns in the intestine.   Millions of Americans are impacted by dysbiosis, which include diseases such as chronic gastrointestinal disease, allergic disorders like asthma, irritable bowel syndrome, ulcerative colitis and Crohn’s disease, fatty liver, metabolic syndrome, type 2 diabetes, Clostridium difficile infection (CDI), chronic neurologic disorders like Parkinson’s and multiple sclerosis and even obesity.  Through our collaboration with TMC institutions, we are uniquely positioned through the Berthelsen Program to treat these diseases.  At the heart of the Berthelsen Program is the concept of research that is both translational, taking basic science to the bedside and also transformational, leading medicine away from expensive, complex and toxic drugs to inexpensive natural methods to produce health that could be cost effective for all, including underserved and developing countries. This approach deals with restoration of body health from the inside out providing the body what is lacking. The Berthelsen Program focuses on a high science-low tech approach to promoting intestinal health with broad applications.

Study Information: B-PRIM, often called Fecal Transplantation, is conducting clinical trials for patients with Recurrent Clostridium Difficile Infection (CDI). The UT Health School of Public Health's Center for Infectious Diseases established PRIM in 2013 and, in affiliation with Kelsey Research Foundation and Kelsey-Seybold Clinic, has treated more than 100 patients with recurrent CDI. To be evaluated for B-PRIM, subjects should have:

  • At least 3 documented recurrences of CDI in the past year inclusive of the recurrent CDI episode or at least 2 episodes of severe CDI resulting in hospitalization;
  • A positive C. difficile toxin test report for most recent CDI (within last 60 days) and at least 2 positive additional C. difficile  test reports; and
  • Completed at least 2 rounds of standard-of-care antibiotic (vancomycin or fidaxomicin) therapy.

For additional study information click here.

Learn more about B-PRIM at:
http://www.fox26houston.com/health/healthworks/103292797-story

Potential subjects please download and complete the Prescreening forms. Forms can be returned via email at: FMT@uth.tmc.edu or via fax to: 713-500-9364.